WARSAW, Ind., Sept. 20, 2016 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the launch of Vanguard® Individualized Design (ID), a first-of-its-kind total knee arthroplasty (TKA) construct designed to enable a personalized fit while simplifying soft tissue preservation and balance. Traditional total knee implants feature a one-piece bearing constructed of polyethylene which is placed between the metal portions of the implant. Vanguard ID is the only TKA design to incorporate two individual polyethylene bearings with different articulations on the medial and lateral sides. The Vanguard ID’s flexible design allows surgeons to mix and match bearings of differing thickness and geometry, ensuring they can personalize their approach to accommodate and preserve natural soft tissue.
“I believe that our newly released Vanguard Individualized Design will revolutionize total knee replacement. With the ability to fine tune the knee’s balance through the use of independent medial and lateral bearing thickness and constraint options, we will arm the surgeon with the ultimate soft tissue respecting capability,” said Todd Davis, Vice President & General Manager of the global Knee business.
The original Vanguard® Knee system, which debuted in 2003, pioneered personalization in knee replacement by offering the broadest range of available sizes. By equipping surgeons to combine a vast number of bearings of varying thickness (up to 2 mm) and articulations to ensure a personalized feel, the Vanguard ID builds on the Vanguard knee’s legacy of enabling surgeons to create a personalized fit, while maintaining surgical simplicity and intraoperative flexibility.
“Maintaining natural ligament tension while preserving healthy soft tissue is critical not only to restore normal range of motion but to achieve patient satisfaction,” said Tom Aleto, M.D. (Missouri Orthopedic Institute, Columbia, Missouri). “In traditional knee design, surgeons typically release healthy soft tissues in an attempt to balance the knee and maintain feasible kinematics. Because the Vanguard ID allows me to mix and match components, I am able to individually treat each compartment while maintaining healthy soft tissues. I personally feel that, by utilizing Vanguard ID and a soft tissue respecting surgical technique, I’m achieving higher patient satisfaction.”
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
SOURCE Zimmer Biomet Holdings, Inc.